A new therapy for osteoporosis: Romosozumab
Osteoporosis is a condition in which bones become porous (less dense) and weaker. It affects 10 million people in the United States: approximately eight million women and two million men. As bone weakens, people are more likely to experience fractures, especially in the spine, hip, and forearm. This causes pain, diminishes a person’s ability to function, and reduces quality of life. Anything that can lower the risk of osteoporosis and fractures has major positive public health implications. That’s why a new drug called romosozumab is getting a lot of attention. Which medications can help treat osteoporosis? The...
Source: Harvard Health Blog - July 17, 2019 Category: Consumer Health News Authors: David M. Slovik, MD Tags: Bones and joints Menopause Osteoporosis Women's Health Source Type: blogs
Hormonal therapy for aggressive prostate cancer: How long is enough?
This study reaffirms what many clinicians have put into practice: longer duration hormonal therapy in appropriately selected patient populations provides a greater benefit,” said Dr. Marc Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of HarvardProstateKnowledge.org. “Prior studies using three years of hormonal therapy have also shown this, but it is important to recognize that some men may have significantly delayed return of the body’s testosterone upon completion of the therapy — a fact that needs to be di...
Source: Harvard Health Blog - January 28, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs
Fight Aging! Newsletter, November 27th 2017
We examined associations between mortality and accelerometer-measured PA using age-relevant intensity cutpoints in older women of various ethnicities. The results support the hypothesis that higher levels of accelerometer-measured PA, even when below the moderate-intensity threshold recommended in current guidelines, are associated with lower all-cause and CVD mortality in women aged 63 to 99. Our findings expand on previous studies showing that higher self-reported PA reduces mortality in adults aged 60 and older, specifically in older women, and at less than recommended amounts. Moreover, our findings challenge th...
Source: Fight Aging! - November 26, 2017 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Bisphosphonates May Act to Reduce Mortality through Vascular Mechanisms
Bisphosphonates are used as a treatment for osteoporosis. Like most pharmaceutical therapies for age-related disease, they have a set of unpleasant side-effects, but a couple of studies have found evidence for long-term bisphosphonate use to reduce mortality in older individuals. In one case the effect was quite large, a dramatic decrease in mortality versus the expected rates. I think there remains some skepticism about an effect of that size resulting from commonly used medications, versus it being an accident of the data or the study group or some other correlated but unrecorded difference, at least until further studie...
Source: Fight Aging! - November 20, 2017 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Vitamin K and Osteoporosis — What ’ s the connection?
Before you are prescribed bisphosphonates: Fosamax, Actonel, Boniva, Reclast or Zometa, maybe you should consider the Undoctored strategy. The grain-free diet, vitamin D, and magnesium protocols in the core Undoctored program provide the bulk of bone health benefits through a variety of mechanisms, including increased intestinal calcium absorption, reduced urinary calcium loss, and reduced levels of the parathyroid hormone that weakens bones. You should also avoid calcium supplements, as the effects of vitamin D and the increased intestinal calcium absorption that develops after eliminating calcium-binding phytates from gr...
Source: Wheat Belly Blog - August 1, 2017 Category: Cardiology Authors: Dr. Davis Tags: Undoctored Vitamin K Wheat Belly Lifestyle anti-aging bowel flora Dr. Davis gluten-free grain-free health osteopenia osteoporosis Wheat Belly Total Health Source Type: blogs
MKSAP: 52-year-old man is evaluated for low back pain
A 52-year-old man is evaluated for low back pain of 3 months’ duration that is nonradiating, progressive, and worse with ambulation. He reports no preceding injury. Medical history is notable for smoldering multiple myeloma diagnosed 1 year ago; he has been stable since that time. His only medication is as-needed acetaminophen. On physical examination, temperature is 36.8 °C (98.2 °F), blood pressure is 132/82 mm Hg, pulse rate is 70/min, and respiration rate is 14/min. No focal neurologic findings are noted. He has pain to palpation of the lower lumbar spine. The remainder of the examination is unremarkable....
Source: Kevin, M.D. - Medical Weblog - July 9, 2016 Category: Journals (General) Authors: mksap Tags: Conditions Radiology Source Type: blogs
Wednesday, May 25, 2016: My sweeties and I bought a nice bouquet of yellow roses to celebrate my latest treatment results. In the last four weeks on Pomalyst (pomalidomide)(POM) and Darzalex (daratumumab)(DARA) my IgG has dropped 20% from 807 to 644 mg/dL, and M-spike 25% from 0.8 to 0.6 g/dL. These numbers are the lowest that I have seen in my 13 years with myeloma. Not all of that progress comes in the last four weeks, of course. Here is a chronology of treatments and results since January, 2016: Wed Feb 17 First Zometa infusion, serious reaction to something, likely the Zometa (not relevant to thes...
Source: Myeloma Hope - May 30, 2016 Category: Cancer & Oncology Tags: daratumumab Darzalex DEX dexamethasone IgG immunoglobulins M-Spike pomalidomide Pomalyst Source Type: blogs
Adventure In Pain
Lots has happened since my last post, and this is a record of those events. I have to write it somewhere. It's interesting to me, part of the journey, but you'll be the judge. It's mostly whining. Background for the reader: Last Wednesday I had an infusion of a study drug and an infusion of Zometa, and also began a week of oral Valtrex in case my back pain might be the prodrome for shingles. By Friday the pain in my back and abdomen was much more pronounced, continuing into Saturday. I posted about that here. Saturday, February 20, 2016: I have a new respect for people who are obliged...
Source: Myeloma Hope - February 24, 2016 Category: Cancer & Oncology Tags: DEX dexamethasone kidney pain Source Type: blogs
Lots More Whining
Just can't get enough of it! Last Wednesday's visit to Mayo Clinic marked the end of the every-week 200-mile round trips, but the results didn't shed much light on my medical condition. Is the "flare" in my vertebrae due to the myeloma itself, or is it inflammation caused by my immune system attacking the myeloma? We're hoping for the latter, of course, and sticking with the current medication study, but this does require more than a little faith. Here is the whining: Last night I was quite uncomfortable for much of the night. The neuropathic pain on the right side of my back beca...
Source: Myeloma Hope - February 20, 2016 Category: Cancer & Oncology Source Type: blogs
Be your own expert!
I was going through papers a few nights ago, when I discovered the handwritten notes that Dr. Richardson (Dana-Farber) had written while I sat in an exam room, there in Boston, in March of 2003. That was 11 years ago. I remember him telling me, “We hope to get you to your 50th birthday — … Read More → (Source: beth's myeloma blog)
Source: beth's myeloma blog - March 11, 2014 Category: Cancer Authors: Beth Tags: Life Myeloma Myeloma Treatment Stem Cell Transplant Zometa Source Type: blogs
Be your own expert!
I was going through papers a few nights ago, when I discovered the handwritten notes that Dr. Richardson (Dana-Farber) had written while I sat in an exam room, there in Boston, in March of 2003. That was 11 years ago. I remember him telling me, “We hope to get you to your 50th birthday — […] (Source: beth's myeloma blog)
Source: beth's myeloma blog - March 11, 2014 Category: Cancer & Oncology Authors: Beth Tags: Life Myeloma Myeloma Treatment Stem Cell Transplant Zometa Source Type: blogs
As Full Disclosure Nears, Doctors’ Pay for Drug Talks Plummets
Some of the nation’s largest pharmaceutical companies have slashed payments to health professionals for promotional speeches amid heightened public scrutiny of such spending, a new ProPublica analysis shows.Eli Lilly and Co.’s payments to speakers dropped by 55 percent, from $47.9 million in 2011 to $21.6 million in 2012.Pfizer’s speaking payments fell 62 percent over the same period, from nearly $22 million to $8.3 million.And Novartis, the largest U.S. drug maker as measured by 2012 sales, spent 40 percent less on speakers that year than it did between October 2010 and September 2011, reducing payments ...
Source: PharmaGossip - March 4, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Supreme Court Rejects Novartis Bid To Hear Punitive Damages Case
In a setback to Novartis, the US Supreme Court has decided not to review a case in which the drugmaker argued that punitive damages should not be awarded by juries in product liability lawsuits. Why? Novartis hoped to convince the court that such penalties purportedly encroach on the ability of the FDA to enforce its authority. As we wrote last week, Novartis cited a 2009 ruling by the Supreme Court that a Vermont woman named Diana Levine had the right to sue Wyeth, which is now owned by Pfizer (PFE), in state court after alleging damage caused by one if its drugs. The drugmaker unsuccessfully cited preemption, which is th...
Source: Pharmalot - October 8, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Should Drugmakers Pay Punitive Damages? Novartis Says No
Should a drugmaker not have to pay punitive damages for product liability because such penalties encroach on the ability of the FDA to enforce its authority? This is the question that Novartis hopes the US Supreme Court will answer in its upcoming session, although whether the justices will agree to review the issue is unclear. A decision may be known next week. In arguing for a review, Novartis cites a 2009 ruling by the Supreme Court that a Vermont woman named Diana Levine had the right to sue Wyeth, which is now owned by Pfizer (PFE), in state court after alleging damage caused by one if its drugs. The drugmaker unsucce...
Source: Pharmalot - October 4, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Flap’s Blog @ Flap Twitter Daily Digest for 2013-08-01
Report: Sen. Graham gets second primary challenger http://t.co/RFjnmMXQO1 #tcot 16:47:14, 2013-08-01 A Gap in the Mouth – Can Primary Care Providers Help With Kids' Oral Health? http://t.co/sqljsihbzG #tcot 16:04:11, 2013-08-01 Osteonecrosis of the Jaw Linked to Adjuvant Zoledronic Acid http://t.co/Ho3behMXJT #tcot 16:04:10, 2013-08-01 Flap's California Blog @ Flap Twitter Digest for 2013-07-31 – Flap's California Blog http://t.co/0XkMtTj5q1 #tcot 16:04:10, 2013-08-01 Flap’s California Blog @ Flap Twitter Digest for 2013-07-31 http://t.co/G1AtqPITQ0 10:45:24, 2013-08-01 Flap's Blog @ F...
Source: FullosseousFlap's Dental Blog - August 2, 2013 Category: Dentists Authors: Flap Tags: Twitter @Flap Tweets Source Type: blogs
June 2013 Lab Values
This is the latest report I have. I had blood drawn at the beginning of June. You can click on the small image of the report to see it full size. It indicates that I’m still stable. From quarter to quarter, there are small changes, but nothing significant. Sometimes the values go up and … Read More → (Source: beth's myeloma blog)
Source: beth's myeloma blog - June 28, 2013 Category: Cancer Authors: Beth Tags: Myeloma Tests Myeloma Treatment curcumin SMM zometa Source Type: blogs